ConferencePoster
 (2026)

AZD4241, an orally bioavailable ERα PROTAC, degrades wild-type and mutant ERα and delivers anti-tumour activity in preclinical breast cancer models

Mandy Lawson; Natalie Cureton; Lynet Nyoni; Sophie D’Arcy; Lydia Parkinson; Ana Quiroga; Pablo Morentin Gutierrez; Ji Li; Hana Baakza; Thomas Hayhow; Claire Crafter; Lucy Ireland; Gemma Hardman Fowler; Georgia M. Simmons; Lakjaya Buluwela; Simak Ali; Neil